Cite
HARVARD Citation
Sulkowski, M. et al. (2018). Efficacy and safety of 6 or 8 weeks of simeprevir, daclatasvir, sofosbuvir for HCV genotype 1 infection. Journal of viral hepatitis. 25 (6), pp. 631-639. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Sulkowski, M. et al. (2018). Efficacy and safety of 6 or 8 weeks of simeprevir, daclatasvir, sofosbuvir for HCV genotype 1 infection. Journal of viral hepatitis. 25 (6), pp. 631-639. [Online].